These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37801804)

  • 1. Feasibility and acceptability of a timeline follow-back method to assess opioid use, non-fatal overdose, and substance use disorder treatment.
    McCann NC; McMahan VM; Smith R; Majeski A; Johns SL; Kosakowski S; Wolfe S; Brennan S; Robinson M; Coffin PO; Walley AY
    Addict Behav; 2024 Jan; 148():107873. PubMed ID: 37801804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.
    Klemperer EM; Wreschnig L; Crocker A; King-Mohr J; Ramniceanu A; Brooklyn JR; Peck KR; Rawson RA; Evans EA
    J Subst Use Addict Treat; 2023 Sep; 152():209103. PubMed ID: 37311520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of an interactive voice response system for daily monitoring of illicit opioid use during buprenorphine treatment.
    Parker MA; Ochalek TA; Rose GL; Badger GJ; Sigmon SC
    Psychol Addict Behav; 2018 Dec; 32(8):956-960. PubMed ID: 30359047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients.
    Crystal S; Nowels M; Samples H; Olfson M; Williams AR; Treitler P
    Drug Alcohol Depend; 2022 Mar; 232():109269. PubMed ID: 35038609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder.
    Shulman M; Choo TH; Scodes J; Pavlicova M; Novo P; Campbell ANC; Greiner M; Lee JD; Rotrosen J; Nunes EV
    J Addict Med; 2023 Sep-Oct 01; 17(5):618-620. PubMed ID: 37788622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of an emergency department-based opioid overdose survivor intervention: Difference-in-difference analysis of electronic health record data to assess key outcomes.
    Watson DP; Weathers T; McGuire A; Cohen A; Huynh P; Bowes C; O'Donnell D; Brucker K; Gupta S
    Drug Alcohol Depend; 2021 Apr; 221():108595. PubMed ID: 33610095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A brief telephone-delivered peer intervention to encourage enrollment in medication for opioid use disorder in individuals surviving an opioid overdose: Results from a randomized pilot trial.
    Winhusen T; Wilder C; Kropp F; Theobald J; Lyons MS; Lewis D
    Drug Alcohol Depend; 2020 Nov; 216():108270. PubMed ID: 32911132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription-related risk factors for opioid-related overdoses in the era of fentanyl contamination of illicit drug supply: A retrospective case-control study.
    Smolina K; Crabtree A; Chong M; Park M; Mill C; Zhao B; Schütz CG
    Subst Abus; 2022; 43(1):92-98. PubMed ID: 32441588
    [No Abstract]   [Full Text] [Related]  

  • 12. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
    Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
    J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
    Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
    Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose.
    Victor GA; Bailey K; Ray B
    Subst Use Misuse; 2021; 56(7):988-996. PubMed ID: 33749520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Opioid Overdose Risk Behavior Scale, version 2 (ORBS-2).
    Elliott L; Crasta D; Khan M; Roth A; Green T; Kolodny A; Bennett AS
    Drug Alcohol Depend; 2021 Jun; 223():108721. PubMed ID: 33895681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose.
    Karmali RN; Ray GT; Rubinstein AL; Sterling SA; Weisner CM; Campbell CI
    Drug Alcohol Depend; 2020 Apr; 209():107923. PubMed ID: 32126455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence.
    Kim TW; Walley AY; Heeren TC; Patts GJ; Ventura AS; Lerner GB; Mauricio N; Saitz R
    J Subst Abuse Treat; 2017 Oct; 81():1-10. PubMed ID: 28847449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a Peer-Led Behavioral Intervention for Emergency Department Patients at High Risk of Fatal Opioid Overdose: A Randomized Clinical Trial.
    Beaudoin FL; Jacka BP; Li Y; Samuels EA; Hallowell BD; Peachey AM; Newman RA; Daly MM; Langdon KJ; Marshall BDL
    JAMA Netw Open; 2022 Aug; 5(8):e2225582. PubMed ID: 35943744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: A pilot randomized controlled trial.
    Coffin PO; Santos GM; Matheson T; Behar E; Rowe C; Rubin T; Silvis J; Vittinghoff E
    PLoS One; 2017; 12(10):e0183354. PubMed ID: 29049282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.